EBS,APVO Stock Quote

EBS [NYSE]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	34.18	EPS (ttm)	3.11	Insider Own	2.50%	Shs Outstand	53.00M	Perf Week	9.32%
Market Cap	5.84B	Forward P/E	11.91	EPS next Y	8.92	Insider Trans	-14.77%	Shs Float	45.20M	Perf Month	19.04%
Income	166.60M	PEG	3.71	EPS next Q	2.83	Inst Own	83.60%	Short Float	4.58%	Perf Quarter	6.77%
Sales	1.33B	P/S	4.38	EPS this Y	-8.50%	Inst Trans	0.26%	Short Ratio	3.75	Perf Half Y	2.01%
Book/sh	23.61	P/B	4.50	EPS next Y	27.00%	ROA	6.90%	Target Price	111.29	Perf Year	89.67%
Cash/sh	7.56	P/C	14.07	EPS next 5Y	9.20%	ROE	14.40%	52W Range	46.37 - 137.61	Perf YTD	18.63%
Dividend	-	P/FCF	21.47	EPS past 5Y	-2.60%	ROI	4.80%	52W High	-22.76%	Beta	1.25
Dividend %	-	Quick Ratio	2.30	Sales past 5Y	22.30%	Gross Margin	64.40%	52W Low	129.22%	ATR	4.48
Employees	1834	Current Ratio	3.20	Sales Q/Q	23.50%	Oper. Margin	19.00%	RSI (14)	66.98	Volatility	4.17% 4.38%
Optionable	Yes	Debt/Eq	0.70	EPS Q/Q	-11.90%	Profit Margin	12.50%	Rel Volume	0.94	Prev Close	105.99
Shortable	Yes	LT Debt/Eq	0.68	Earnings	Nov 05 AMC	Payout	0.00%	Avg Volume	551.25K	Price	106.29
Recom	1.90	SMA20	10.29%	SMA50	18.44%	SMA200	15.72%	Volume	518,545	Change	0.28%

Jan-08-21

Downgrade

Wells Fargo

Overweight → Equal Weight

$110

Sep-14-20

Resumed

JP Morgan

Neutral

$103

Jul-31-20

Reiterated

Chardan Capital Markets

Buy

$86 → $112

Sep-12-19

Initiated

Guggenheim

Buy

Sep-04-19

Upgrade

Wells Fargo

Market Perform → Outperform

Nov-02-18

Upgrade

Goldman

Neutral → Buy

Aug-03-18

Reiterated

Chardan Capital Markets

Buy

$53 → $57

Jun-13-18

Initiated

Argus

Buy

$62

Apr-25-18

Downgrade

Wells Fargo

Outperform → Market Perform

Jan-24-18

Initiated

Goldman

Neutral

Jan-16-18

Reiterated

Chardan Capital Markets

Buy

$47 → $53

Jun-28-16

Reiterated

Singular Research

Buy

$44 → $40

Apr-15-16

Initiated

Chardan Capital Markets

Buy

$47

Mar-28-16

Initiated

Singular Research

Buy

$44

Feb-19-16

Initiated

Wells Fargo

Outperform

May-15-14

Initiated

Summer Street Research

Buy

$35

May-31-11

Reiterated

WBB Securities

Strong Buy

$20.50 → $30

Jan-10-11

Reiterated

Wedbush

Outperform

$27 → $32

Nov-05-10

Reiterated

Wedbush

Outperform

$22 → $27

Aug-18-10

Upgrade

WBB Securities

Buy → Strong Buy

$20.50

Jan-13-21 01:38PM	Emergent BioSolutions Sees Its Composite Rating Rise To 97 Investor's Business Daily
Jan-12-21 10:37AM	Emergent BioSolutions Is Looking Stronger TheStreet.com
Jan-11-21 09:22AM	Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View Zacks
09:15AM	How to Play Emergent BioSolutions Right Now TheStreet.com
Jan-10-21 02:00PM	Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results GlobeNewswire
Jan-07-21 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Emergent Biosolutions (EBS) Zacks
Jan-06-21 05:50PM	Emergent Biosolutions (EBS) Outpaces Stock Market Gains: What You Should Know Zacks
11:30AM	Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year? Zacks
Jan-05-21 07:03AM	Is Emergent BioSolutions Stock a Buy? Motley Fool
Jan-04-21 03:25PM	England Goes Under National Lockdown Barrons.com
06:30AM	Emergent BioSolutions to Participate in Investor Conferences GlobeNewswire
Dec-31-20 09:40AM	Company News for Dec 31, 2020 Zacks
Dec-30-20 11:21AM	Emergent BioSolutions Secures DOD Aid for Covid Treatment Test TheStreet.com
Dec-29-20 04:05PM	Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis GlobeNewswire
Dec-18-20 08:15PM	Is EBS A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-17-20 09:19AM	20 best mid-cap stocks for 2021, according to analysts MarketWatch
Dec-16-20 11:56PM	Is Now The Time To Put Emergent BioSolutions (NYSE:EBS) On Your Watchlist? Simply Wall St.
Dec-15-20 09:38AM	Emergent BioSolutions Inc. -- Moody's announces completion of a periodic review of ratings of Emergent Biosolutions Inc. Moody's
Dec-05-20 11:32AM	Emergent Biosolutions (EBS) Down 14.7% Since Last Earnings Report: Can It Rebound? Zacks
Dec-02-20 12:35PM	Is Emergent BioSolutions (EBS) a Smart Long-term Buy? Insider Monkey
Nov-27-20 06:14AM	3 Bargain Stocks You Can Buy Today Motley Fool
Nov-18-20 09:30AM	Is Emergent BioSolutions (EBS) a Good Stock to Pick Now? Zacks -5.38%
Nov-10-20 09:40AM	Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study Data Zacks
Nov-09-20 10:18AM	Deciphera (DCPH) Reports Narrower-Than-Expected Loss in Q3 Zacks
08:58AM	Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus Zacks
Nov-06-20 06:50PM	Why Emergent BioSolutions Slipped on Friday Motley Fool
11:16AM	Emergent (EBS) Beats on Q3 Earnings, Tapers '20 Sales View Zacks
10:57AM	BioMarin (BMRN) Beats on Q3 Earnings, Lowers Sales View Zacks
10:54AM	Global Blood (GBT) Q3 Loss Wider Than Expected, Sales Miss Zacks
10:52AM	Amicus' (FOLD) Q3 Loss Wider Than Expected, Revenues Beat Zacks
10:51AM	Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates Zacks
10:43AM	Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact Zacks
08:00AM	Coronavirus Stocks Are Up Big This Year, But Which Ones Should You Buy? Investor's Business Daily
Nov-05-20 07:40PM	Emergent Biosolutions (EBS) Q3 Earnings Top Estimates Zacks
04:05PM	Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance GlobeNewswire
03:15PM	Emergent BioSolutions, Inc. to Host Earnings Call ACCESSWIRE
11:38AM	Zoetis' (ZTS) Q3 Earnings and Revenues Surpass Estimates Zacks
08:58AM	Zoetis (ZTS) in Focus: Stock Moves 6.9% Higher Zacks
Nov-04-20 09:52AM	Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses Zacks +5.95%
Nov-03-20 10:29AM	Apellis Pharmaceuticals' (APLS) Q3 Loss Wider Than Expected Zacks
10:26AM	Bayer's (BAYRY) Q3 Earnings & Sales Miss Estimates, Down Y/Y Zacks
10:14AM	Horizon (HZNP) Q3 Earnings Top Estimates, Tepezza Drives Sales Zacks
09:36AM	Esperion (ESPR) Q3 Earnings Top, Coronavirus Woes Linger Zacks
Nov-02-20 12:46PM	What's in Store for Emergent (EBS) This Earnings Season? Zacks
11:06AM	Ligand (LGND) Q3 Earnings & Sales Fall Short of Estimates Zacks
Oct-30-20 03:54PM	Alkermes (ALKS) Beats on Q3 Earnings & Sales, Lifts Guidance Zacks
Oct-29-20 05:45PM	Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know Zacks
02:25PM	Sarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating Investor's Business Daily
12:34PM	Emergent Biosolutions (EBS) Earnings Expected to Grow: Should You Buy? Zacks
11:24AM	Dr. Reddy's (RDY) Q2 Earnings Decline Y/Y, Sales Increase Zacks
Oct-28-20 10:32AM	Ultragenyx (RARE) Loss Narrows Y/Y, Revenues Beat Estimates Zacks
Oct-23-20 05:45PM	Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know Zacks
Oct-21-20 11:30AM	Has Emergent Biosolutions (EBS) Outpaced Other Medical Stocks This Year? Zacks
10:48AM	Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II Zacks
Oct-20-20 10:26AM	Aptose (APTO) Initiates Phase I a/b Study in Leukemia Patients Zacks
Oct-19-20 10:09AM	Regeneron's (REGN) Dupixent Gets Positive CHMP Opinion for Dermatitis Zacks
10:05AM	ASLAN Pharmaceuticals (ASLN) in Focus: Stock Moves 7% Higher Zacks
09:55AM	Alnylam (ALNY) Gets Positive CHMP Opinion for Lumasiran Zacks
Oct-16-20 09:58AM	Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study Zacks
08:54AM	Anavex (AVXL) in Focus: Stock Moves 9.5% Higher Zacks
Oct-15-20 05:45PM	Emergent Biosolutions (EBS) Gains As Market Dips: What You Should Know Zacks
12:45PM	3 Reasons Growth Investors Will Love Emergent Biosolutions (EBS) Zacks
10:24AM	Bayer's Aliqopa Meets Primary Endpoint in Lymphoma Study Zacks
Oct-14-20 10:03AM	AnaptysBio Shares Up on Positive Top-Line Psoriasis Data Zacks
Oct-13-20 12:31PM	Why Emergent BioSciences Stock Is Falling Today Motley Fool -13.64%
10:36AM	Dow Jones Falls As These 2 Key Stocks Weigh, But Nasdaq Briefly Turns Higher Investor's Business Daily
10:32AM	Immunomedics' Trodelvy Gets Orphan Drug Tag for Glioblastoma Zacks
10:30AM	Alexion's Ultomiris Gets FDA Approval for New Formulation Zacks
09:47AM	Return On Capital Employed Overview: Emergent BioSolutions Benzinga
09:45AM	The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher Zacks
08:30AM	Aileron Therapeutics (ALRN) in Focus: Stock Moves 6.5% Higher Zacks
Oct-12-20 09:45AM	Booming Gene Editing Market to Pep Up These 5 Biotech Stocks Zacks
08:50AM	SpringWorks Therapeutics (SWTX) Surges: Stock Moves 9.6% Higher Zacks
Oct-09-20 08:40AM	Rhythm Pharmaceuticals (RYTM) Looks Good: Stock Adds 5.1% in Session Zacks
08:32AM	Gamida Cell (GMDA) Jumps: Stock Rises 8.4% Zacks
Oct-08-20 04:05PM	Emergent BioSolutions COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19 GlobeNewswire
11:37AM	Kindred Shares Up on Expansion of Agreement With Vaxart Zacks
08:37AM	Alexion (ALXN) in Focus: Stock Moves 7.9% Higher Zacks
Oct-07-20 10:49AM	Iovance Stock Down on Delay in Filing for Melanoma Candidate Zacks
10:46AM	Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint Zacks
Oct-06-20 09:19AM	Regeneron (REGN) in Focus: Stock Moves 7.1% Higher Zacks +5.07%
Oct-05-20 12:46PM	Hedge Funds Are Piling Into Emergent Biosolutions Inc (EBS) Insider Monkey +5.64%
11:30AM	Is Emergent Biosolutions (EBS) Stock Outpacing Its Medical Peers This Year? Zacks
Sep-21-20 04:25AM	Emergent BioSolutions Sees Hammer Chart Pattern: Time to Buy? Zacks
Sep-18-20 11:30AM	Has Emergent Biosolutions (EBS) Outpaced Other Medical Stocks This Year? Zacks
Sep-16-20 12:19PM	Stocks Showing Market Leadership: Atara Biotherapeutics Earns 92 RS Rating Investor's Business Daily
Sep-15-20 10:48AM	Sangamo Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold Investor's Business Daily
Sep-11-20 05:50PM	Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know Zacks
Sep-10-20 12:11PM	Sangamo Therapeutics Getting Closer To Key Technical Benchmark Investor's Business Daily
Sep-08-20 04:34AM	BiohavenPharmaHldg Reaches 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
Sep-04-20 11:41AM	Stocks To Watch: Arena Pharmaceuticals Sees Relative Strength Rating Rise To 83 Investor's Business Daily
Sep-02-20 11:30AM	Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year? Zacks
09:55AM	The Zacks Analyst Blog Highlights: Stamps.com, Etsy, Daqo New Energy, Emergent BioSolutions and Atlas Air Worldwide Zacks
Sep-01-20 10:10AM	Spero's (SPRO) IND Accepted by FDA for Pulmonary Disease Drug Zacks
Aug-31-20 06:30AM	Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day GlobeNewswire
Aug-29-20 11:31AM	Emergent Biosolutions (EBS) Up 21.2% Since Last Earnings Report: Can It Continue? Zacks
Aug-26-20 01:33PM	Kura Oncology Clears Key Benchmark, Hitting 90-Plus RS Rating Investor's Business Daily
01:11PM	Stocks To Watch: Insmed Sees RS Rating Rise To 83 Investor's Business Daily
12:23PM	Stock Upgrades: Amgen Shows Rising Relative Strength Investor's Business Daily
08:04AM	Emergent BioSolutions' Shares March Higher, Can It Continue? Zacks

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
El-Hibri Fuad	Chairman	Nov 10	Option Exercise	26.45	19,391	512,892	1,143,379	Nov 12 06:30 PM
El-Hibri Fuad	Chairman	Nov 10	Sale	88.21	19,391	1,710,480	1,123,988	Nov 12 06:30 PM
El-Hibri Fuad	Chairman	Nov 09	Option Exercise	26.45	20,000	529,000	1,143,988	Nov 12 06:30 PM
El-Hibri Fuad	Chairman	Nov 09	Sale	95.26	20,000	1,905,200	1,123,988	Nov 12 06:30 PM
El-Hibri Fuad	Chairman	Nov 03	Option Exercise	26.45	20,000	529,000	1,143,988	Nov 04 08:53 PM
El-Hibri Fuad	Chairman	Nov 03	Sale	90.74	20,000	1,814,800	1,123,988	Nov 04 08:53 PM
El-Hibri Fuad	Chairman	Nov 02	Option Exercise	26.45	20,000	529,000	1,143,988	Nov 04 08:53 PM
El-Hibri Fuad	Chairman	Nov 02	Sale	90.44	20,000	1,808,800	1,123,988	Nov 04 08:53 PM
El-Hibri Fuad	Chairman	Sep 24	Sale	98.85	12,535	1,239,085	1,123,988	Sep 25 07:00 PM
El-Hibri Fuad	Chairman	Sep 23	Sale	100.58	13,000	1,307,540	1,136,523	Sep 25 07:00 PM
El-Hibri Fuad	Chairman	Sep 17	Sale	100.68	20,000	2,013,600	1,149,523	Sep 18 06:25 PM
El-Hibri Fuad	Chairman	Sep 16	Sale	102.48	20,000	2,049,600	1,169,523	Sep 18 06:25 PM
El-Hibri Fuad	Chairman	Sep 10	Sale	102.66	20,000	2,053,200	1,189,523	Sep 11 09:21 PM
El-Hibri Fuad	Chairman	Sep 09	Sale	102.80	20,000	2,056,000	1,209,523	Sep 11 09:21 PM
SULLIVAN LOUIS W	Director	Sep 02	Option Exercise	20.08	7,893	158,491	50,655	Sep 04 08:08 PM
SULLIVAN LOUIS W	Director	Sep 02	Sale	111.22	28,418	3,160,606	42,762	Sep 04 08:08 PM
Bailey Sue	Director	Aug 18	Sale	128.31	4,665	598,564	32,595	Aug 19 05:08 PM
Harsanyi Zsolt	Director	Aug 17	Sale	133.71	6,609	883,664	24,579	Aug 18 09:12 AM
JOULWAN GEORGE A	Director	Aug 11	Sale	124.11	6,000	744,635	26,771	Aug 12 04:52 PM
Zoon Kathryn C	Director	Aug 10	Sale	130.27	1,000	130,270	12,489	Aug 11 04:43 PM
Richard Ronald	Director	Aug 07	Sale	131.00	6,297	824,907	8,276	Aug 11 04:46 PM
Richard Ronald	Director	Jun 03	Sale	87.51	6,572	575,142	4,269	Jun 05 04:36 PM
Bailey Sue	Director	Jun 03	Sale	87.50	5,322	465,691	37,260	Jun 05 04:33 PM
Hauer Jerome M	Director	May 26	Sale	85.15	4,385	373,373	10,188	May 27 05:10 PM
Zoon Kathryn C	Director	May 26	Sale	85.10	4,093	348,322	13,489	May 27 05:07 PM
Harsanyi Zsolt	Director	May 14	Option Exercise	18.64	3,434	64,010	28,367	May 18 07:12 PM
Zoon Kathryn C	Director	May 12	Sale	85.21	1,660	141,454	14,761	May 14 04:30 PM
Harsanyi Zsolt	Director	May 11	Sale	81.99	4,940	405,025	24,933	May 13 07:47 PM
JOULWAN GEORGE A	Director	May 11	Sale	85.19	2,000	170,371	29,950	May 13 07:45 PM
Richard Ronald	Director	May 05	Sale	80.19	8,375	671,629	8,020	May 06 05:08 PM
El-Hibri Fuad	Chairman	Apr 30	Sale	74.01	20,000	1,480,200	1,229,523	May 01 08:13 PM
El-Hibri Fuad	Chairman	Apr 29	Sale	74.24	20,000	1,484,800	1,249,523	May 01 08:13 PM
Richard Ronald	Director	Apr 27	Option Exercise	20.08	7,893	158,491	24,288	Apr 29 04:35 PM
Richard Ronald	Director	Apr 27	Sale	78.00	7,893	615,654	16,395	Apr 29 04:35 PM
El-Hibri Fuad	Chairman	Apr 23	Sale	68.49	20,000	1,369,800	1,269,523	Apr 24 04:16 PM
El-Hibri Fuad	Chairman	Apr 22	Sale	66.81	20,000	1,336,200	1,289,523	Apr 24 04:16 PM
Havey Adam	EVP, Business Operations	Apr 20	Option Exercise	30.86	17,009	524,898	51,265	Apr 21 06:12 PM
Havey Adam	EVP, Business Operations	Apr 20	Sale	69.00	17,009	1,173,621	34,256	Apr 21 06:12 PM
Havey Adam	EVP, Business Operations	Apr 17	Option Exercise	26.45	20,414	539,950	54,670	Apr 21 06:12 PM
Havey Adam	EVP, Business Operations	Apr 17	Sale	65.00	20,414	1,326,910	34,256	Apr 21 06:12 PM
El-Hibri Fuad	Chairman	Apr 16	Sale	62.47	20,000	1,249,400	1,309,523	Apr 20 06:30 PM
El-Hibri Fuad	Chairman	Apr 15	Sale	62.58	12,537	784,565	1,329,523	Apr 15 09:04 PM
El-Hibri Fuad	Chairman	Apr 14	Sale	62.99	6,261	394,380	1,342,060	Apr 15 09:04 PM
El-Hibri Fuad	Chairman	Apr 13	Sale	62.25	17,071	1,062,670	1,348,321	Apr 15 09:04 PM
El-Hibri Fuad	Chairman	Apr 09	Sale	61.83	23,716	1,466,360	1,365,392	Apr 10 07:13 PM
El-Hibri Fuad	Chairman	Apr 08	Sale	61.13	37,362	2,284,115	1,389,108	Apr 10 07:13 PM
El-Hibri Fuad	Chairman	Apr 07	Sale	60.76	14,336	871,055	1,426,470	Apr 08 09:17 PM
Kirk Sean	EVP, Manufacturing & Tech Ops	Apr 06	Option Exercise	30.70	10,428	320,131	19,864	Apr 08 08:19 PM
El-Hibri Fuad	Chairman	Apr 06	Sale	60.50	28,240	1,708,520	1,440,806	Apr 08 09:17 PM
Havey Adam	EVP, Business Operations	Apr 06	Sale	60.00	7,972	478,320	34,256	Apr 08 08:22 PM
Kirk Sean	EVP, Manufacturing & Tech Ops	Apr 06	Sale	60.00	16,094	965,640	12,571	Apr 08 08:19 PM
Harsanyi Zsolt	Director	Mar 16	Sale	65.00	6,400	416,000	29,873	Mar 17 04:39 PM
SULLIVAN LOUIS W	Director	Mar 04	Option Exercise	13.86	15,786	218,715	68,359	Mar 06 04:37 PM
Zoon Kathryn C	Director	Mar 04	Sale	60.65	991	60,103	16,421	Mar 06 04:39 PM
SULLIVAN LOUIS W	Director	Mar 04	Sale	58.96	15,786	930,714	60,466	Mar 06 04:37 PM
Bailey Sue	Director	Feb 27	Sale	56.93	6,572	374,132	39,761	Mar 02 05:28 PM
El-Hibri Fuad	Chairman	Feb 27	Sale	56.97	9,837	560,414	1,469,046	Feb 28 08:01 PM
El-Hibri Fuad	Chairman	Feb 26	Sale	58.70	13,619	799,435	1,472,943	Feb 28 08:01 PM
El-Hibri Fuad	Chairman	Feb 21	Option Exercise	25.62	18,567	475,687	1,497,585	Feb 24 08:00 PM
Richard Ronald	Director	Feb 21	Option Exercise	18.64	5,152	96,033	31,851	Feb 25 04:30 PM
Richard Ronald	Director	Feb 21	Sale	65.00	5,152	334,880	16,395	Feb 25 04:30 PM
Hauer Jerome M	Director	Feb 21	Sale	70.00	6,572	460,040	11,752	Feb 25 04:28 PM
El-Hibri Fuad	Chairman	Feb 21	Sale	64.90	18,567	1,204,998	1,479,018	Feb 24 08:00 PM
El-Hibri Fuad	Chairman	Feb 20	Option Exercise	25.62	4,751	121,721	1,483,769	Feb 24 08:00 PM
El-Hibri Fuad	Chairman	Feb 20	Sale	64.90	4,751	308,340	1,479,018	Feb 24 08:00 PM
El-Hibri Fuad	Chairman	Feb 18	Option Exercise	25.62	15,614	400,031	1,494,632	Feb 19 09:00 PM
El-Hibri Fuad	Chairman	Feb 18	Sale	63.90	15,614	997,735	1,479,018	Feb 19 09:00 PM
El-Hibri Fuad	Chairman	Feb 14	Option Exercise	25.62	4,386	112,369	1,483,404	Feb 19 09:00 PM
El-Hibri Fuad	Chairman	Feb 14	Sale	63.90	4,386	280,265	1,479,018	Feb 19 09:00 PM
El-Hibri Fuad	Chairman	Feb 12	Option Exercise	25.62	13,720	351,506	1,492,738	Feb 13 06:30 PM
El-Hibri Fuad	Chairman	Feb 12	Sale	62.90	13,720	862,988	1,479,018	Feb 13 06:30 PM
El-Hibri Fuad	Chairman	Feb 11	Option Exercise	25.62	6,280	160,894	1,485,298	Feb 13 06:30 PM
El-Hibri Fuad	Chairman	Feb 11	Sale	62.90	6,280	395,012	1,479,018	Feb 13 06:30 PM
El-Hibri Fuad	Executive Chairman	Feb 06	Sale	61.90	11,684	723,240	1,419,018	Feb 07 06:31 PM
El-Hibri Fuad	Executive Chairman	Feb 05	Sale	60.66	48,316	2,930,849	1,430,702	Feb 07 06:31 PM

open in screener | open in yahoo | open in reuters | open in google

publish chart | save to portfolio | create alert

APVO [NASD]

Aptevo Therapeutics Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-10.15	Insider Own	5.93%	Shs Outstand	3.23M	Perf Week	-13.10%
Market Cap	131.67M	Forward P/E	-	EPS next Y	-5.29	Insider Trans	-	Shs Float	1.35M	Perf Month	-20.40%
Income	-32.90M	PEG	-	EPS next Q	-1.22	Inst Own	75.20%	Short Float	12.28%	Perf Quarter	361.46%
Sales	11.00M	P/S	11.97	EPS this Y	54.10%	Inst Trans	180.29%	Short Ratio	0.09	Perf Half Y	314.67%
Book/sh	0.68	P/B	47.81	EPS next Y	-16.00%	ROA	-56.10%	Target Price	-	Perf Year	234.12%
Cash/sh	6.15	P/C	5.29	EPS next 5Y	-	ROE	-199.50%	52W Range	2.94 - 60.00	Perf YTD	-11.30%
Dividend	-	P/FCF	-	EPS past 5Y	15.40%	ROI	-	52W High	-45.82%	Beta	7.49
Dividend %	-	Quick Ratio	-	Sales past 5Y	-6.60%	Gross Margin	44.10%	52W Low	1004.20%	ATR	2.33
Employees	80	Current Ratio	4.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	36.67	Volatility	6.40% 6.63%
Optionable	No	Debt/Eq	11.45	EPS Q/Q	37.40%	Profit Margin	-	Rel Volume	0.04	Prev Close	33.82
Shortable	Yes	LT Debt/Eq	11.45	Earnings	-	Payout	-	Avg Volume	1.79M	Price	32.51
Recom	1.70	SMA20	-11.18%	SMA50	-15.96%	SMA200	120.02%	Volume	73,145	Change	-3.87%

Nov-05-18

Initiated

Ladenburg Thalmann

Buy

Oct-05-17

Resumed

Piper Jaffray

Overweight

Jan-11-21 08:00AM	Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial ACCESSWIRE
Jan-06-21 12:00PM	Aptevo Therapeutics Inc. (APVO) Upgraded to Buy: Here's Why Zacks
Dec-19-20 01:45PM	Kaskela Law LLC Announces Investigation of Aptevo Therapeutics Inc. (APVO) and Encourages Shareholders to Contact the Firm ACCESSWIRE
Dec-02-20 08:00AM	Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442 ACCESSWIRE +8.30%
Nov-20-20 07:37AM	The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga
Nov-19-20 04:15PM	Aptevo Confirms Receipt of Unsolicited Indication of Interest ACCESSWIRE +29.10%
Nov-16-20 08:00AM	Aptevo Therapeutics and Alligator Bioscience Advancing the Bispecific 4-1BBx5T4 Antibody ALG.APV-527 Into Phase 1 Clinical Development ACCESSWIRE -8.85%
Nov-10-20 08:40AM	The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga +35.37%
Nov-09-20 09:00AM	Aptevo Therapeutics to Present at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting ACCESSWIRE +38.14%
06:00AM	Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial ACCESSWIRE
Nov-08-20 11:15PM	Aptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan ACCESSWIRE
Nov-03-20 09:00AM	Aptevo Therapeutics Announces First Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial ACCESSWIRE +78.25%
Sep-01-20 09:00AM	Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial ACCESSWIRE
Aug-14-20 09:00AM	Aptevo Therapeutics Reports Second Quarter 2020 Financial Results ACCESSWIRE +7.85%
Aug-06-20 09:00AM	Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust ACCESSWIRE
Jul-21-20 09:00AM	Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones ACCESSWIRE
Jun-30-20 12:00PM	All You Need to Know About Aptevo Therapeutics Inc. (APVO) Rating Upgrade to Buy Zacks -9.92%
11:30AM	Has Aptevo Therapeutics (APVO) Outpaced Other Medical Stocks This Year? Zacks
Jun-29-20 09:00AM	Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale ACCESSWIRE +13.05%
Jun-25-20 09:00AM	Aptevo Therapeutics to receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar ACCESSWIRE +55.83%
Jun-10-20 09:00AM	Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit ACCESSWIRE
May-13-20 09:00AM	Aptevo Therapeutics Reports First Quarter 2020 Financial Results ACCESSWIRE -7.11%
Apr-14-20 09:00AM	Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements ACCESSWIRE +15.20%
Mar-25-20 09:00AM	Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update ACCESSWIRE
Mar-16-20 09:00AM	Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial ACCESSWIRE +19.11%
Feb-28-20 09:05AM	Aptevo Therapeutics Sells IXINITY Hemophilia B Therapy for Estimated Proceeds in Excess of $100 Million ACCESSWIRE +8.89%
08:59AM	Medexus Expands its US Product Portfolio by Acquiring the Hematology Asset IXINITY® GlobeNewswire
Jan-30-20 09:00AM	Aptevo Therapeutics Doses First Patient in IXINITY Clinical Trial for Potential Pediatric Label Expansion ACCESSWIRE
Jan-13-20 08:00AM	Aptevo Therapeutics' APVO436 Selected For Inclusion In The Leukemia & Lymphoma Society's Groundbreaking BEAT AML(R) Master Clinical Trial ACCESSWIRE
Dec-19-19 03:50PM	Aptevo Therapeutics Inc. (APVO): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-06-19 09:00AM	Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia GlobeNewswire
Nov-12-19 09:00AM	What Makes Aptevo Therapeutics Inc. (APVO) a New Buy Stock Zacks
Nov-08-19 09:00AM	Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting GlobeNewswire +7.39%
Nov-07-19 09:00AM	Aptevo Therapeutics Reports Third Quarter 2019 Financial Results GlobeNewswire
Oct-04-19 07:32AM	The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering Benzinga +6.93%
Oct-03-19 04:02PM	Aptevo Therapeutics Provides Corporate and Pipeline Update Globenewswire Test
04:02PM	Aptevo Therapeutics Provides Corporate and Pipeline Update GlobeNewswire
Sep-19-19 09:00AM	Aptevo Therapeutics Introduces New Adaptir Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors GlobeNewswire
Aug-09-19 09:00AM	Aptevo Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire -9.67%
Aug-07-19 09:02AM	Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited GlobeNewswire
Jul-25-19 04:32PM	Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials GlobeNewswire
Jun-25-19 09:00AM	Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients GlobeNewswire -5.99%
May-09-19 09:00AM	Aptevo Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-29-19 10:21AM	The Zacks Analyst Blog Highlights: Advanced Emissions, Aptevo, BankFinancial, Good Times and Health Insurance Zacks
Apr-26-19 08:31AM	5 Stocks to Gain From Dollar's Recent Strength Zacks
Apr-15-19 09:00AM	Aptevo Therapeutics Reports IXINITY® and Pipeline Progress GlobeNewswire
Apr-11-19 12:26PM	What Kind Of Investor Owns Most Of Aptevo Therapeutics Inc. (NASDAQ:APVO)? Simply Wall St.
Apr-02-19 09:02AM	Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting GlobeNewswire
Mar-25-19 09:02AM	Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting GlobeNewswire +6.67%
Mar-20-19 09:02AM	Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases GlobeNewswire
Mar-18-19 09:00AM	Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update GlobeNewswire +6.10%
Mar-14-19 10:28AM	Aptevo Therapeutics Inc. (APVO) Moves to Buy: Rationale Behind the Upgrade Zacks
Mar-07-19 09:13AM	Aptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants GlobeNewswire -40.20%
Mar-06-19 04:37PM	Aptevo Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire +5.71%
Jan-07-19 08:30AM	Aptevo Therapeutics Highlights Key 2019 Priorities GlobeNewswire
Jan-03-19 09:02AM	Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics GlobeNewswire
Dec-21-18 09:00AM	Aptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital GlobeNewswire -9.29%
Dec-20-18 12:57PM	Need To Know: Aptevo Therapeutics Inc. (NASDAQ:APVO) Insiders Have Been Buying Shares Simply Wall St. -11.95%
Dec-13-18 09:02AM	Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436 GlobeNewswire -6.98%
Dec-11-18 07:20AM	United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-20-18 09:00AM	Aptevo Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-14-18 04:02PM	Aptevo Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-09-18 12:00AM	Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting GlobeNewswire -5.88%
Oct-24-18 09:00AM	Aptevo Therapeutics Announces Expanded Growth Initiatives for IXINITY GlobeNewswire -12.88%
Oct-10-18 08:40AM	Market Trends Toward New Normal in Aptevo Therapeutics, Bottomline Technologies, Allete, Air Lease, The Goodyear Tire & Rubber, and EastGroup Properties Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Sep-25-18 11:29AM	Aptevo Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire
Sep-05-18 11:36AM	Here's Why Momentum Investors Will Love Aptevo Therapeutics Inc. (APVO) Zacks
Aug-31-18 02:46PM	Penny Stocks to Buy Using Technical Analysis for September 2018 Investopedia
Aug-09-18 09:00AM	Aptevo Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-07-18 09:00AM	Aptevo Therapeutics Revises Term Loan Agreement With MidCap Financial; Reduces Cash Requirements by $18 Million GlobeNewswire
Aug-06-18 08:10AM	Report: Developing Opportunities within athenahealth, W.R. Berkley, Air Products and Chemicals, DICK'S Sporting Goods, Aptevo Therapeutics, and Columbia Property Trust Future Expectations, Projections Moving into 2018 GlobeNewswire
May-29-18 09:00AM	Novel First-In-Class Immunotherapeutic APVO210 Features Unique Mechanism of Action Delivering IL-10 GlobeNewswire
May-15-18 07:40AM	Wired News Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases ACCESSWIRE +17.10%
May-10-18 09:00AM	Aptevo Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire +14.22%
May-08-18 09:02AM	New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences GlobeNewswire
May-01-18 09:00AM	Aptevo Therapeutics Announces IND Submission for APVO436 GlobeNewswire
Apr-30-18 07:50AM	Report: Developing Opportunities within Natus Medical, Aptevo Therapeutics, Revlon, Silgan, Resources Connection, and TrustCo Bank Corp NY Future Expectations, Projections Moving into 2018 GlobeNewswire
Apr-20-18 08:35PM	Aptevo executive Jane Gross jumped to a startup and landed in the C-Suite American City Business Journals
Apr-16-18 09:02AM	Aptevo Therapeutics Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release GlobeNewswire +17.99%
Mar-19-18 08:20AM	Research Report Identifies Ambarella, Merit Medical, NETGEAR, Independent Bank, Cutera, and Aptevo Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-13-18 09:02AM	Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update GlobeNewswire
Mar-12-18 09:02AM	Aptevo Therapeutics Presents New Patient-Reported Data With IXINITY GlobeNewswire
Feb-27-18 09:02AM	Aptevo Therapeutics to Present at the 30th Annual ROTH Conference GlobeNewswire
Jan-17-18 08:10AM	Report: Exploring Fundamental Drivers Behind Anthera Pharmaceuticals, Alarm, Aptevo Therapeutics, Shoe Carnival, Independent Bank, and First Internet New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-11-18 09:04AM	How Is Bioverativs Alprolix Positioned Now? Market Realist
Jan-08-18 09:00AM	Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma GlobeNewswire
Jan-03-18 08:17AM	Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 3, 2018 Capital Cube
Dec-27-17 10:58AM	ETFs with exposure to Aptevo Therapeutics, Inc. : December 27, 2017 Capital Cube
Dec-19-17 09:05AM	Does Aptevo Therapeutics Incs (NASDAQ:APVO) 74.9% EPS Growth Reflect The Long-Term Trend? Simply Wall St.
Dec-11-17 01:28PM	ETFs with exposure to Aptevo Therapeutics, Inc. : December 11, 2017 Capital Cube
09:02AM	Aptevo Therapeutics Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML Samples GlobeNewswire
Nov-29-17 10:58AM	ETFs with exposure to Aptevo Therapeutics, Inc. : November 29, 2017 Capital Cube
Nov-28-17 07:02AM	Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study of Otlertuzumab in Peripheral T-Cell Lymphoma GlobeNewswire
Nov-21-17 06:39PM	Is Aptevo Therapeutics Incs (APVO) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Nov-14-17 04:02PM	Aptevo Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-09-17 04:30PM	Aptevo Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-01-17 11:50AM	ETFs with exposure to Aptevo Therapeutics, Inc. : November 1, 2017 Capital Cube
Oct-30-17 09:02AM	Aptevo Therapeutics Presents New Preclinical Data on APVO436 a Next Generation ADAPTIR Bispecific Antibody Candidate GlobeNewswire
Oct-24-17 09:00AM	Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics GlobeNewswire
Oct-16-17 09:02AM	Aptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society Meeting GlobeNewswire

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TANG KEVIN C	10% Owner	Nov 06	Buy	22.73	174,277	3,961,898	1,760,000	Nov 06 04:47 PM
TANG KEVIN C	10% Owner	Nov 05	Buy	18.78	625,723	11,750,307	1,585,723	Nov 06 04:47 PM
TANG KEVIN C	10% Owner	Nov 04	Buy	14.35	636,675	9,137,026	960,000	Nov 06 04:47 PM

open in screener | open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience